Jump to content
Powered by

China Medical City, Taizhou

Taizhou is a commercial and industrial city of around 5 million inhabitants, located in the Yantze River Delta about half way between Nanjing and Suzhou. Within the Taizhou city boundaries, on a total area of 25 square kilometers (about one-quarter the area of Tuebingen), China Medical City (CMC), a national-level pharmaceutical high-tech park, is currently under construction.

China medical city logo © www.youtube.com

The China Medical City will contain zones for R&D, manufacturing, exhibition and trade, further a large hospital (healthcare and service zone), a university (education zone) and areas for administration and living.

Research & development and manufacturing will be focused on five areas:
a) vaccines
b) biopharmaceuticals
c) new chemical entities (NCEs)
d) high-end medical apparatus and instruments and
e) extraction technologies for traditional Chinese medicines (TCM).

Efforts have been made to recruit overseas Chinese entrepreneurs for this endeavour.

Building of Beike Biotechnology Co. Ltd.
Beike Biotechnology Co. Ltd. © Stemindo Medika Cemerlang

Examples are Dr. Sean HU, CEO, and Dr. Qing Yun SONG, VP for Medical, Scientific and Regulatory Affairs, of Beike Biotech Co., the operator of Jiangsu Stem Cell Bank located at CMC.
Beike Biotech Co. is a public-private partnership, which isolates embryonal stem cells from the umbelical cord of newborn babies and stores them for lifelong availability at a price of 22000 RMB (approx. 2500 €). The Jiangsu Stem Cell Bank features the presently largest stem cell storage and processing unit, for up to 100.000 stem cell samples. Beike Biotechnology focuses on stem cell research and clinical application. It currently offers a full line of stem cell products derived from umbilical cord, cord blood, peripheral blood and bone marrow.
Stem cells work by providing the body with paracrine mediators and cytokines as well as a variety of other cell factors. These help to encourage the following physiological functions:

1. Immune system regulation
2. Reducing cell death
3. Stimulation of growth of the patient’s own stem cells
4. Neo-angiogenesis (the growth of blood vessels resulting in increased blood flow to damaged areas)
5. Scar tissue reduction
6. Improving the effective conduction of intercellular electrical signals and transduction

Beike’s research for future therapies is focused mainly on iPS (induced pluripotent stem cells) technology in partnership with various leading scientific groups including Tsinghua Unversity. Cooperation with international partners to help verify the effectiveness of treatments and protocols and to license other technologies for use throughout Bike’s network of twenty seven hospitals is very welcome.
The company was founded with capital from Beijing University, Hong Kong University of Science and Technology, and Shenzhen City Hall. The formation of the company was also supported by grants from the China State National Fund. Since that time, additional capital has been provided by a variety of Chinese venture capital firms. In total, Beike has received over US$ 6 million in Chinese government grants including a grant for a joint laboratory in Shenzhen with Tsingua University to focus on the study of stem cell reprogramming.

Beike‘s head office is located in Shenzhen but the company also has offices in Beijing, Nanjing, Taizhou, and Qingdao.

In January 2010, both Beike Biotechnology Stem Cell Preparation Laboratory and Beike's Jiangsu Stem Cell Bank received ISO9001 Quality Management System Authentication from the China Quality Center (CQC). The stem cell bank was the first comprehensive storage facility to receive this authentication in China.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/china-medical-city-taizhou